Sean Ekins cv

1,907 views

Published on

curriculum vitae

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,907
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Sean Ekins cv

  1. 1. Sean Ekins [email_address] Collaborations In Chemistry Resume
  2. 2. Experience <ul><li>Over 14 years of applied pharmaceutical company experience </li></ul><ul><li>Computational ( in silico ) drug discovery, QSAR and pharmacophore application, systems biology applied to pathway and biomarker discovery, in vitro methods, drug-drug interactions and computational ADME/TOX. </li></ul><ul><li>Successfully obtained NIH SBIR phase I and II grant funding as a principal investigator at different companies. </li></ul><ul><li>Valuable start-up company experience leading and managing teams of international scientists and collaborators, directing technology development and scientific research . </li></ul>
  3. 3. Key Academic Qualifications <ul><li>Nottingham Trent University </li></ul><ul><ul><li>HND Science (Applied Biology) </li></ul></ul><ul><li>University of Aberdeen </li></ul><ul><ul><li>M.Sc. Clinical Pharmacology </li></ul></ul><ul><ul><li>Ph.D. Medicine and Therapeutics (Clinical Pharmacology) </li></ul></ul><ul><ul><li>D.Sc. Science </li></ul></ul>
  4. 4. Key Positions – Diversity of Experience <ul><li>Post doc - Eli Lilly </li></ul><ul><ul><li>1996-1998 </li></ul></ul><ul><li>Research Scientist – Pfizer </li></ul><ul><ul><li>1998-1989 </li></ul></ul><ul><li>Senior Computational Chemist – Eli Lilly </li></ul><ul><li>1999- 2001 </li></ul><ul><li>Associate Director, Computational Drug Discovery - Concurrent Pharmaceuticals </li></ul><ul><ul><li>2001- 2004 </li></ul></ul><ul><li>Vice President, Computational Biology </li></ul><ul><ul><li>2004- 2006 </li></ul></ul><ul><li>Senior Consultant, Collaborations in Chemistry </li></ul><ul><ul><li>2007 - present </li></ul></ul>
  5. 5. Adjunct Positions <ul><li>Adjunct Professor, Robert Wood Johnson Medical School, University of Medicine and Dentistry New Jersey, July 2007-present. </li></ul><ul><li>Adjunct Associate Professor, School of Pharmacy Department of Pharmaceutical Sciences, University of Maryland. MD, Jan 2005-present. </li></ul>
  6. 6. Leadership Competencies <ul><li>Collaboration and influencing: An outward facing scientist able to collaborate for mutual success and deliver on milestones. </li></ul><ul><li>Team leadership: An experienced cross-functional leader with effective communication skills. </li></ul><ul><li>Commercial orientation: Vast experience from pharma and biotech collaborations at identifying and obtaining opportunities for funding and applying leading edge technologies. </li></ul><ul><li>Results orientation: An intellectual and scientific risk taker who delivers beyond expectations. </li></ul><ul><li>Strategic orientation: Possesses a broad perspective of drug discovery and development. </li></ul>
  7. 7. Strengths <ul><li>Research innovation for drug discovery </li></ul><ul><ul><li>Computational ADME/Tox Pioneer </li></ul></ul><ul><ul><li>Pharmacophore building expert </li></ul></ul><ul><ul><li>Broad cheminformatics skills for drug discovery </li></ul></ul><ul><ul><li>Technology development – e.g. MetaDrug which brought cheminformatics and systems biology together as an award winning commercial product </li></ul></ul><ul><li>Writing papers and book chapters– over 150 since 1995 </li></ul><ul><ul><li>Many with over 100 citations </li></ul></ul><ul><ul><li>Web of Science h-factor = 33 (whatever value that has!) </li></ul></ul><ul><li>Writing grants that get funded – 5 NIH grants to date as PI </li></ul><ul><li>Book Series editing for Wiley </li></ul><ul><li>Scientific Visionary – advocate of collaboration for over a decade </li></ul>
  8. 8. Consulting For Clients <ul><li>Collaborative Drug Discovery </li></ul><ul><ul><li>www.collaborativedrug.com </li></ul></ul><ul><ul><li>BMGF funded grant on TB </li></ul></ul><ul><ul><li>STTR funded project </li></ul></ul><ul><li>Merck </li></ul><ul><li>Longevica Pharmaceuticals </li></ul><ul><li>Ardelyx Pharmaceuticals </li></ul>
  9. 9. Key Papers in 2010 <ul><li>Ekins S , Kaneko T, Lipinski CA, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Ernst S, Yang J, Goncharoff N, Hohman M and Bunin BA, Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis, Mol BioSyst In Press 2010. </li></ul><ul><li>Rishi R. Gupta, Gifford, EM, Liston T, Waller CL, Hohman M, Bunin BA and Ekins S , Using open source computational tools for predicting human metabolic stability and additional ADME/Tox properties, Drug Metab Dispos, In Press, 2010. </li></ul><ul><li>Ekins S and Williams EJ, When Pharmaceutical Companies Publish Large Datasets: An Abundance of riches or fool’s gold?, Drug Disc Today, In Press 2010. </li></ul><ul><li>Ekins S , Gupta R, Gifford E, Bunin BA, Waller CL, Chemical Space: missing pieces in cheminformatics, Pharm Res, In Press 2010. </li></ul><ul><li>Kortagere S, Krasowski MD, Reschly EJ, Venkatesh M, Mani S and Ekins S , Evaluation of Computational Docking to Identify PXR Agonists in the ToxCastTM Database Env Health Perspect, In Press 2010. </li></ul><ul><li>Ekins S , Honeycutt JD and Metz JT, Evolving molecules using multi-objective optimization: applying to ADME/Tox, Drug Disc Today, 15: 451-460, 2010. </li></ul><ul><li>Arnold RJG and Ekins S , Time for cooperation in health economics among the modeling community, PharmacoEconomics, 28(8):609-613, 2010. </li></ul><ul><li>Ekins S . and Williams AJ, Reaching out to collaborators: crowdsourcing for pharmaceutical research, Pharm Res, 27: 393-395, 2010. </li></ul><ul><li>Ekins S and Williams AJ, Precompetitive Preclinical ADME/Tox Data: Set It Free on The Web to Facilitate Computational Model Building to Assist Drug Development. Lab On A Chip, 10: 13-22, 2010. </li></ul><ul><li>Zientek M, Stoner C, Ayscue R, Klug-McLeod J, Jiang Y, West M, Collins C and Ekins S , Integrated In Silico- In vitro strategy for addressing Cytochrome P450 3A4 time dependent inhibition, Chem Res Toxicol, 23: 664-676, 2010. </li></ul><ul><li>Ekins S , Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Hohman M and Bunin BA, A Collaborative Database and Computational Models for Tuberculosis Drug Discovery, Mol BioSyst, 6: 840-851, 2010. </li></ul>
  10. 10. Books I have edited since 2006
  11. 11. Editorial Positions <ul><li>Associate Editor: Journal of Pharmacological and Toxicological Methods, since Jan 2001 </li></ul><ul><li>Editorial Board: Drug Metabolism and Disposition, since 2003, Drug Discovery Today, since 2005, The Open Drug Delivery Journal 2007-2009, Current Drug Metabolism 2007-2009, Drug Metabolism Letters since 2007-2009. Pharmaceutical Research (Editor of Reviews) since 2009, Mutation Research-Reviews since 2009, The ChemSpider Journal of Chemistry 2009. </li></ul><ul><li>Editorial Advisory Board: Pharmaceutical Research, 2006-2008 </li></ul>
  12. 12. Grants <ul><li>NIH Grants </li></ul><ul><li>2R44GM069124-02 In Silico Assessment of Drug Metabolism and Toxicity, SBIR phase II (principal investigator) Funded (~$750,000 total cost) from 08/01/05 to 08/01/07. </li></ul><ul><li>1R43NS061376-01 Targeted Aggregation Inhibitors for the Treatment of Amyloid Diseases, SBIR phase I (principal investigator) Funded ($124,425 total cost) from 10/01/07 to 03/31/2008 </li></ul><ul><li>1R43CA130183-01A1 Computer-Aided Design, Synthesis, And Testing Of A Novel Family Of Triazole-Based Anticancer Therapeutics, SBIR phase I (principal investigator) Funded (Total cost $114,818) From 05/01/08- 10/31/08 </li></ul><ul><li>1R43AI078763-01A1 Development of an Inhibitor of Toxoplasma gondii, NIAID Advanced Technology SBIR (principal investigator on proposal submitted then replaced upon leaving company) Funded (Total cost $638,000) </li></ul><ul><li>1R41AI088893-01 Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic based pathway analysis, STTR phase I (Principal Investigator) Funded (Total cost $149,382) 07/01/11 – 06/30/11 </li></ul><ul><li>European Grants </li></ul><ul><li>Part of the consortia for the framework grant More Medicines for Tuberculosis </li></ul><ul><li>Specific Programme “Cooperation” – Theme &quot;Health&quot; </li></ul><ul><li>Call identifier: FP7-HEALTH-2010-single-stage </li></ul><ul><li>Proposal No: 260872 </li></ul><ul><li>Acronym: MM4TB </li></ul>
  13. 13. Research Interests <ul><li>Collaboration </li></ul><ul><li>Nuclear receptors (PXR, FXR, LXR, VDR modeling) </li></ul><ul><li>P450 modeling </li></ul><ul><li>Transporter modeling </li></ul><ul><li>hERG modeling </li></ul><ul><li>Crowdsourcing </li></ul>

×